Abstract
Angiogenesis and the development of a vascular network are required for tumour progression, and they involve the release of angiogenic factors, including vascular endothelial growth factor (VEGF-A), from both malignant and stromal cell types1. Infiltration by cells of the myeloid lineage is a hallmark of many tumours, and in many cases the macrophages in these infiltrates express VEGF-A2. Here we show that the deletion of inflammatory-cell-derived VEGF-A attenuates the formation of a typical high-density vessel network, thus blocking the angiogenic switch in solid tumours in mice. Vasculature in tumours lacking myeloid-cell-derived VEGF-A was less tortuous, with increased pericyte coverage and decreased vessel length, indicating vascular normalization. In addition, loss of myeloid-derived VEGF-A decreases the phosphorylation of VEGF receptor 2 (VEGFR2) in tumours, even though overall VEGF-A levels in the tumours are unaffected. However, deletion of myeloid-cell VEGF-A resulted in an accelerated tumour progression in multiple subcutaneous isograft models and an autochthonous transgenic model of mammary tumorigenesis, with less overall tumour cell death and decreased tumour hypoxia. Furthermore, loss of myeloid-cell VEGF-A increased the susceptibility of tumours to chemotherapeutic cytotoxicity. This shows that myeloid-derived VEGF-A is essential for the tumorigenic alteration of vasculature and signalling to VEGFR2, and that these changes act to retard, not promote, tumour progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Folkman, J. Angiogenesis. Annu. Rev. Med. 57, 1–18 (2006)
Lewis, J. S., Landers, R. J., Underwood, J. C., Harris, A. L. & Lewis, C. E. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J. Pathol. 192, 150–158 (2000)
Gerber, H. et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nature Med. 5, 623–628 (1999)
Clausen, B. E., Burkhardt, C., Reith, W., Renkawitz, R. & Forster, I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8, 265–277 (1999)
Cramer, T. et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 112, 645–657 (2003)
Guy, C. T., Cardiff, R. D. & Muller, W. J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12, 954–961 (1992)
Lin, E. Y. et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. 163, 2113–2126 (2003)
Grunstein, J., Roberts, W. G., Mathieu-Costello, O., Hanahan, D. & Johnson, R. S. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res. 59, 1592–1598 (1999)
Lin, E. Y. et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 66, 11238–11246 (2006)
Mayer, E. L., Lin, N. U. & Burstein, H. J. Novel approaches to advanced breast cancer: bevacizumab and lapatinib. J. Natl. Compr. Canc. Netw. 5, 314–323 (2007)
Hurwitz, H. I., Honeycutt, W., Haley, S. & Favaro, J. Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report. Clin. Colorectal Cancer 6, 66–69 (2006)
Gerber, H. P. et al. VEGF is required for growth and survival in neonatal mice. Development 126, 1149–1159 (1999)
Acknowledgements
We thank J. DuRose, N. Ferrara, L. Iruela-Arispe, L. Coussens, M. Karin, V. Nizet and H.-P. Gerber for helpful conversations. Financial support was provided by the Deutsche Forschungsgemeinschaft to C.S. (STO 787/1-1) and A.W. (WE 4275/1-1), a Susan G. Komen Dissertation Research Award (DISS0402406) to A.D., and National Institutes of Health grants CA82515, CA118165 and AI060840 to R.S.J.
Author Contributions C.S. generated isografts, conducted drug treatment studies, performed biochemical experiments, immunohistochemical procedures and histological analysis, and prepared the manuscript. A.D. generated MMTV-PyMT/LysMCre/VEGF+f/+f mice, conducted related tumour palpation/mass studies, initial histology and flow cytometry, and assisted with the manuscript. A.W. generated VEGF-null fibroblasts. N.Z. performed preliminary cDNA studies on MMTV-PyMT/LysMCre/VEGF+f/+f tumours. N.T. assisted with the fluorescein isothiocyanate-dextran angiography. J.I.G. and D.A.C. provided confocal microscopy images and technical advice. R.S.J. supervised and directed the project.
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Supplementary Information
This file contains Supplementary Figures 1-4 with Legends (PDF 6180 kb)
Rights and permissions
About this article
Cite this article
Stockmann, C., Doedens, A., Weidemann, A. et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456, 814–818 (2008). https://doi.org/10.1038/nature07445
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature07445
This article is cited by
-
Migrasomes, a new mode of intercellular communication
Cell Communication and Signaling (2023)
-
Macrophage numbers in the marginal area of sarcomas predict clinical prognosis
Scientific Reports (2023)
-
CCL21-CCR7 signaling promotes microglia/macrophage recruitment and chemotherapy resistance in glioblastoma
Cellular and Molecular Life Sciences (2023)
-
Monocytes deposit migrasomes to promote embryonic angiogenesis
Nature Cell Biology (2022)
-
Tumor-associated myeloid cells: diversity and therapeutic targeting
Cellular & Molecular Immunology (2021)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.